Making medical technology easier to access, by the general population, is a new paradigm for the medical community. Finding ways to bring the technology to the people could open entirely new markets and access to once undiagnosed patients.
Telzuit Medical Technologies, Inc., a medical technology company working to design and market medical ambulatory devises, has been experiencing positive results as this relates to the company’s ongoing financial performance. Although the company has a somewhat limited product development pipeline, it has been seeing a positive direction with the two revenue sources that is/has developed. The company’s product base is oriented around 2 free standing clinics, 6 mobile imaging clinics and its STATPATCH SYSTEM.
Currently, the clinic and mobile imaging portions of the company are contributing to the lion’s share of revenue. Realized and projected revenue streams have been met and exceeded while strict cost controls have kept development expenses under control. Ultimately, the STATPATCH SYSTEM product and its potential revenue stream should become the company’s leading contributor to revenue with its multiple billing options.
The STATPATCH SYSTEM is a 12 patch system that attaches to the patient’s body. The system then transmits near real time data through wireless signals to a belt worn PDA devise for data storage and access. Conjecture may indicate that this devise was the original intent of the company’s product base followed by the clinics. It has since found secondary revenue status as clinic sales increase and STATPATCH SYSTEM rollout continues. Revenues for STATPATCH SYSTEM are derived from; system sales, third party billing, patch sales, direct billing to physicians per PDA access and per PDA access from the company owned PDA. Rollout of the system continues in a limited form.
Telzuit Medical Technologies operates primarily in the central Florida region but has designs for a national presence in the near future. Stockholder meetings have been planned in several locations around the country so initial stock investors and potential stock investors may be kept well informed. Although there have been a few minor setbacks with the PDA devise, the over 100 million resting EKG readings and 80 million doctors’ office visits each year, in the United States alone, bode well for the company.
Let us hear your thoughts below:
